"The “negative voices” concentrating on the flaws in the FDA’s approval as “not pro-patient.”"
Before its Aduhelm decision, we believe the FDA’s worst approval in recent memory belonged to Exondys 51, a drug to treat Duchenne muscular dystrophy.
Before its Aduhelm decision, we believe the FDA’s worst approval in recent memory belonged to Exondys 51, a drug to treat Duchenne muscular dystrophy.